Pharma and biotechnology major Biocon's net profit for the second quarter ended September 30 went up 4.6 per cent to Rs 90 crore, compared to the same period last year.
The Bangalore-based company's total income for the three-month period ended September 30, stood at Rs 628.5 crore registering a growth of 22.4 per cent when compared to the same period last year. On a sequential basis, the net profit grew 14 per cent while the revenues reported a growth of nine per cent. On Wednesday, the company’s share price hit Rs 267.7 on the BSE.
During the period under review, the company said its branded formulations business recorded a robust year on year growth of 45 per cent to Rs 178 crore.
The company announced that it has signed an agreement with GE Equity International, a subsidiary of the GE Capital Corporation, which will make a primary equity investment in Syngene International Ltd, Biocon’s research services subsidiary. According to the agreement, GE Capital will invest Rs 125 crore for a 7.69 per cent equity share in Syngene. Kiran Mazumdar-Shaw, chairman and managing director, Biocon, said, “This takes us closer to our commitment of taking Syngene through an IPO at the most opportune moment.” Syngene, posted revenue of Rs 400 crore in FY12, and registered sales of about Rs 250 crore in the first half of the current fiscal, the company said.
Biocon also said that the Global Phase 3 clinical study for its recombinant human insulin in Type 1 diabetes mellitus patients demonstrates comparable safety and efficacy with the innovator product.
On the BSE, the shares of the company closed at Rs 265.55 up 2.55 per cent as against previous day's closing.
The trial has met its efficacy end point with a comparable immunogenicity and safety profile. The second part of the study evaluating additional safety and immunogenicity parameters is ongoing, it added.